Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
about
sameAs
Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical StudiesLong-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in GermanyAntiplatelet therapy in populations at high risk of atherothrombosisThe current state of drug discovery and a potential role for NMR metabolomics.Cost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Platelet P2 receptors: old and new targets for antithrombotic drugs.Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerationsAntiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.Cost of noninfectious comorbidities in patients with HIV.Interpreting the results of cost-effectiveness studies.The cost-effectiveness of clopidogrel: a review by indication.Cost-effectiveness of oral antiplatelet agents--current and future perspectives.Cost-effectiveness of ticagrelor in acute coronary syndromes.Optimizing the use of aspirin for cardiovascular prevention.The road not taken: transferability issues in multinational trials.Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.Cost-effectiveness of clopidogrel: seeing through the smoke.Platelet transcriptome and cardiovascular disease.Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy.Transfemoral aortic valve implantation: bleeding events, related costs and outcomes.Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial.Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.Comparative Review of Oral P2Y12 Inhibitors.
P2860
Q28083366-48AF307D-1927-4457-AB0B-4F7B04B437EEQ28213339-990C741C-F6CB-44DC-9B95-518F01408A4AQ28218702-3B446ECC-A43A-46F4-89D2-2D74441B6D16Q35072850-D8C9BDAF-4615-4D2C-8515-FC6ACD68F63BQ35216895-4361630A-0E55-43D2-86F7-71E192B1293FQ35752598-F6F18BB9-C035-4E79-8144-0E8055CF2CC9Q36691632-7050A02F-4515-4D28-BD17-72781101AC3AQ36703074-817AA164-ED22-49D6-B2FC-B4CF181F883EQ36754513-5E42B941-1CCC-4510-892D-40B2B659D72AQ36892804-A97451D4-81EF-4DE1-9081-248498920212Q37119060-62116C8D-0CA4-4D63-9D71-ACD87B8371ADQ37213494-4BE21FC3-7237-4CB1-BDB7-8177AE5337A9Q37276134-D7A90EEE-F759-4968-9A80-0070DBB6EE41Q37763176-C3A081A8-A8B0-496E-A69E-D25232D6851FQ37913974-3FE337B4-0FBD-4510-A802-CB953F0C55C2Q38080910-5FAD6868-45A9-4A41-9FDD-B25E877C5E13Q38107179-E6A195AD-6517-4CAF-BEEC-1194690ACE1FQ38131747-D910F488-E2E0-4795-8170-563287F3EAA2Q38469251-3D7A7F5B-7109-4240-886A-051246A6E7D9Q39616458-6E65EFAA-F437-49C8-9B5F-6036EC8C6D74Q40080904-A73BA183-84C3-4714-8A4C-8C18CB57C0BAQ40199232-B66D56FC-5A8E-4F09-8EC9-8C4221F24E44Q43266392-C34C0A7B-AAD2-4402-9289-A4C7D4EFEC97Q43436123-577E4A36-5ADC-4EB7-8829-2333905BC400Q45301806-4201A301-2686-4BE6-9CAF-ED2B73C0A22EQ46582354-BB9CCE96-4686-4137-9431-416B323557E9Q50126504-2F985C6C-7022-4F10-82B6-FCE5B0CC4DEAQ55396201-96505806-F21E-4D1F-AC49-A659063C5C0C
P2860
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Long-term cost-effectiveness o ...... s without ST-segment elevation
@ast
Long-term cost-effectiveness o ...... s without ST-segment elevation
@en
Long-term cost-effectiveness o ...... s without ST-segment elevation
@nl
type
label
Long-term cost-effectiveness o ...... s without ST-segment elevation
@ast
Long-term cost-effectiveness o ...... s without ST-segment elevation
@en
Long-term cost-effectiveness o ...... s without ST-segment elevation
@nl
prefLabel
Long-term cost-effectiveness o ...... s without ST-segment elevation
@ast
Long-term cost-effectiveness o ...... s without ST-segment elevation
@en
Long-term cost-effectiveness o ...... s without ST-segment elevation
@nl
P2093
P1476
Long-term cost-effectiveness o ...... s without ST-segment elevation
@en
P2093
Andre Lamy
Elizabeth M Mahoney
Salim Yusuf
Steven Culler
Sylvie Gabriel
William S Weintraub
P304
P356
10.1016/J.JACC.2004.11.051
P407
P50
P577
2005-03-15T00:00:00Z